Susquehanna International Group, LLP V Tv Therapeutics Inc. Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.42 - $0.75 $23,508 - $41,979	-55,973 Reduced 73.41%	20,278 $9,000
Q2 2023 Aug 11, 2023	BUY	$0.72 - $0.95 $43,906 - $57,931	60,981 Added 399.35%	76,251 $56,000
Q1 2023 May 16, 2023	BUY	$0.72 - $1.01 $10,994 - $15,422	15,270 New	15,270 $12,000
Q3 2022 Nov 14, 2022	BUY	$0.65 - $38.8 $1,010 - $60,333	1,555 Added 7.52%	22,233 $22,000
Q2 2022 Aug 15, 2022	SELL	$0.39 - $0.84 $959 - $2,067	-2,461 Reduced 10.64%	20,678 $16,000
Q1 2022 May 16, 2022	BUY	$0.51 - $1.0 $11,800 - $23,139	23,139 New	23,139 $17,000
Q3 2021 Nov 15, 2021	SELL	$1.53 - $2.22 $65,413 - $94,913	-42,754 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$2.27 - $3.44 $97,051 - $147,073	42,754 New	42,754 $97,000
Q2 2020 Aug 14, 2020	SELL	$1.74 - $3.19 $28,355 - $51,984	-16,296 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.63 - $3.75 $26,562 - $61,110	16,296 New	16,296 $31,000

243K

Ticker VTVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,483,600
Market Cap $1.27B
Description
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetran...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.